Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 3, 2011 - Issue
Submit an article Journal homepage
530
Views
69
CrossRef citations to date
0
Altmetric
Review

Biosimilar medicines and cost-effectiveness

Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumCorrespondence[email protected]
Pages 29-36 | Published online: 10 Feb 2011

Citations (69)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (17)

Kadir Ulu, Mustafa Çakan, Şengül Çağlayan, Ramazan Emre Yiğit, Ferhat Demir, Taner Coşkuner, Esra Kardeş & Betül Sözeri. (2023) Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases. Expert Opinion on Biological Therapy 23:8, pages 833-839.
Read now
Fatma Gül Demirkan, Kadir Ulu, Kübra Öztürk, Şerife Gül Karadağ, Semanur Özdel, Hafize Emine Sönmez, Figen Çakmak, Ferhat Demir, Betül Sözeri & Nuray Aktay Ayaz. (2022) Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy 22:2, pages 197-202.
Read now
Sadia Shakeel, Mohamed Azmi Hassali, Hina Rehman, Anees ur Rehman & Jaya Muneswarao. (2020) Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists. International Journal of General Medicine 13, pages 1075-1082.
Read now
Kashyap B Patel, Luiz H Arantes$suffix/text()$suffix/text(), Wing Yu Tang & Selwyn Fung. (2018) The role of biosimilars in value-based oncology care. Cancer Management and Research 10, pages 4591-4602.
Read now
Rajamannar Thennati, Sanjay Kumar Singh, Nitin Nage, Yena Patel, Sandip Kumar Bose, Vinod Burade & Ranjit Sudhakar Ranbhor. (2018) Analytical characterization of recombinant hCG and comparative studies with reference product. Biologics: Targets and Therapy 12, pages 23-35.
Read now
Martin Sheppard, Faidra Laskou, Philip P. Stapleton, Shahryar Hadavi & Bhaskar Dasgupta. (2017) Tocilizumab (Actemra). Human Vaccines & Immunotherapeutics 13:9, pages 1972-1988.
Read now
Valderílio Feijó Azevedo, Ludmila Della Coletta Troiano, Natalia Bassalobre Galli, Alais Kleinfelder, Nathan M Catolino & Paulo Cesar Urbano Martins. (2016) Adalimumab: a review of the reference product and biosimilars. Biosimilars 6, pages 29-44.
Read now
Dominika Neumann & Anna Jabłecka. (2016) Reimbursement of biosimilars in Poland: is there a link to health technology assessment?. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 781-792.
Read now
Jason R Guertin, Dominic Mitchell, Farzad Ali & Jacques LeLorier. (2015) Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug. ClinicoEconomics and Outcomes Research 7, pages 497-503.
Read now
Brian Bressler & Theo Dingermann. (2015) Establishing a new marketplace for biologic therapy with biosimilar agents: importance of extrapolation of data. Biosimilars 5, pages 41-48.
Read now
Mary Lynn Davis-Ajami, Jun Wu, Katherine Downton, Emilie Ludeman & Virginia Noxon. (2014) Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics: Targets and Therapy 8, pages 155-167.
Read now
Walter Jeske, Jeanine M Walenga, Debra Hoppensteadt & Jawed Fareed. (2013) Update on the safety and bioequivalence of biosimilars – focus on enoxaparin. Drug, Healthcare and Patient Safety 5, pages 133-141.
Read now
Zayrho Desanvicente-Celis, Julian Caro-Moreno, Mateo Enciso-Zuluaga & Juan-Manuel Anaya. (2013) Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases. Biosimilars 3, pages 1-17.
Read now
Zaina P Qureshi, Jametta S Magwood, Sarveshwari Singh & Charles L Bennett. (2013) Rituximab and biosimilars – equivalence and reciprocity. Biosimilars 3, pages 19-25.
Read now
V Fragoulakis, E Kastritis, T Psaltopoulou & N Maniadakis. (2013) Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Management and Research 5, pages 37-48.
Read now
Paul J Declerck & Steven Simoens. (2012) A European perspective on the market accessibility of biosimilars. Biosimilars 2, pages 33-40.
Read now
Andrew W. Wilson & Peter J. Neumann. (2012) The cost-effectiveness of biopharmaceuticals. mAbs 4:2, pages 281-288.
Read now

Articles from other publishers (52)

Sherin Ismail, Laila Abu Esba, Mansoor Khan, Hana Al-Abdulkarim, Hind Modimagh & Consuela Yousef. (2022) An Institutional Guide for Formulary Decisions of Biosimilars. Hospital Pharmacy 58:1, pages 38-48.
Crossref
Christina Mitropoulou, Vasileios Fragoulakis, James Buchanan, Sarah Wordsworth & George P. Patrinos. 2023. Economic Evaluation in Genomic and Precision Medicine. Economic Evaluation in Genomic and Precision Medicine 1 14 .
Hala Najeeb, Farah Yasmin & Salim Surani. (2022) Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World Journal of Clinical Cases 10:14, pages 4327-4333.
Crossref
Gina Wong, Katie Wang, Mark Pasetka, Liying Zhang, Julia Lou, Habeeb Majeed, Jerome Flores, Emily Lam & Carlo DeAngelis. (2022) The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study. Current Oncology 29:3, pages 1349-1369.
Crossref
Gina Wong, Liying Zhang, Habeeb Majeed, Yasmeen Razvi, Carlo DeAngelis, Emily Lam, Erin McKenzie, Katie Wang & Mark Pasetka. (2020) A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®). Journal of Oncology Pharmacy Practice 28:1, pages 5-16.
Crossref
Clara Grazia Chisari, Eleonora Sgarlata, Sebastiano Arena, Simona Toscano, Maria Luca & Francesco Patti. (2021) Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology 269:1, pages 159-183.
Crossref
Marie-Therese Schnorbach & Wolfgang Kruis. (2020) Krankheitskosten chronisch entzündlicher Darmerkrankungen in Deutschland. Zeitschrift für Gastroenterologie 59:11, pages 1173-1188.
Crossref
Olga Barszczewska & Anna Piechota. (2021) The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences. International Journal of Environmental Research and Public Health 18:13, pages 6952.
Crossref
Thomas Perez, Audrey Rico, Clémence Boutière, Adil Maarouf, Marjorie Roudot, Stéphane Honoré, Jean Pelletier, Pierre Bertault-Peres & Bertrand Audoin. (2020) Comparison of rituximab originator (MabThera ® ) to biosimilar (Truxima ® ) in patients with multiple sclerosis . Multiple Sclerosis Journal 27:4, pages 585-592.
Crossref
José F. Santos-Neto, Fabricia O. Oliveira, Katharine V. S. Hodel, Larissa M. S. Fonseca, Roberto Badaró & Bruna A. S. Machado. (2021) Technological Advancements in Monoclonal Antibodies. The Scientific World Journal 2021, pages 1-19.
Crossref
Brigida Barberio, Linda Cingolani, Cristina Canova, Giulia Barbieri, Renato Sablich, Maria Teresa Urbano, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Antonio Ferronato, Andrea Buda, Piera Melatti, Davide Massimi, Edoardo Vincenzo Savarino & Fabiana Zingone. (2021) A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Therapeutic Advances in Gastroenterology 14, pages 175628482110314.
Crossref
Bruna de Oliveira Ascef, Ana Carolina de Freitas Lopes & Patrícia Coelho de Soárez. (2020) Health technology assessment of biosimilars worldwide: a scoping review. Health Research Policy and Systems 18:1.
Crossref
Hui-Yao Huang, Cheng-Cheng Liu, Yue Yu, Le Wang, Da-Wei Wu, Lan-Wei Guo, Shu-Hang Wang, Hong Fang, Ying Bai, Yuan Fang, Qi Fan, Chao Sun, Ying Wu, Ju-Fang Shi, Fei Ma, Yu Tang, Min Dai & Ning Li. (2020) Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review. Frontiers in Pharmacology 11.
Crossref
Kelly A. Reynolds, Deeti J. Pithadia, Erica B. Lee, Wilson Liao & Jashin J. Wu. (2020) Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. American Journal of Clinical Dermatology 21:4, pages 483-491.
Crossref
Binita Dutta, Isabelle Huys, Arnold G. Vulto & Steven Simoens. (2019) Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. BioDrugs 34:2, pages 159-170.
Crossref
Mansoor A. Khan, Mohammed A. Aseeri, Majed A. Alshamrani, Abdelmajid H. Alnatsheh & Hani S. Alhamdan. (2020) Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective. Global Journal on Quality and Safety in Healthcare 3:1, pages 22-29.
Crossref
Amit Garg, Deepak CSN & Tarveen Jandoo. 2019. Advances in Hematologic Malignancies. Advances in Hematologic Malignancies.
Sofia Konstantinidou, Angeliki Papaspiliou & Eleni Kokkotou. (2019) Current and future roles of biosimilars in oncology practice (Review). Oncology Letters.
Crossref
Ari Brekkan, Luis Lopez-Lazaro, Elodie L. Plan, Joakim Nyberg, Suresh Kankanwadi & Mats O. Karlsson. (2019) Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies. The AAPS Journal 21:5.
Crossref
Christopher Ma, Robert Battat, Parambir S. Dulai, Claire E. Parker, William J. Sandborn, Brian G. Feagan & Vipul Jairath. (2019) Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 79:12, pages 1321-1335.
Crossref
Jichun Yang, Shuqing Yu, Zhirong Yang, Yusong Yan, Yao Chen, Hongmei Zeng, Fei Ma, Yanxia Shi, Yehui Shi, Zilu Zhang & Feng Sun. (2019) Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BioDrugs 33:4, pages 357-371.
Crossref
Fiorenzo Santoleri, Alessia Romagnoli & Alberto Costantini. (2019) Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital. Future Oncology 15:1, pages 45-51.
Crossref
María Ángeles Piñero-López, Carlos Figueiredo-Escribá, Pilar Modamio, Cecilia F Lastra & Eduardo L Mariño. (2019) Readability assessment of package leaflets of biosimilars. BMJ Open 9:1, pages e024837.
Crossref
Brian K Link. (2018) Biosimilars: when a negative study can be positive. The Lancet Haematology 5:11, pages e500-e501.
Crossref
Don Husereau, Brian Feagan & Carl Selya-Hammer. (2018) Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. Applied Health Economics and Health Policy 16:3, pages 279-288.
Crossref
Fadi Farhat, Alfredo Torres, Wungki Park, Gilberto de Lima Lopes, Raja Mudad, Chukwuemeka Ikpeazu & Simon Abi Aad. (2018) The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review. The Oncologist 23:3, pages 346-352.
Crossref
Rakesh ChopraGilberto Lopes. (2017) Improving Access to Cancer Treatments: The Role of Biosimilars. Journal of Global Oncology 3:5, pages 596-610.
Crossref
Steven Simoens, Ira Jacobs, Robert Popovian, Leah Isakov & Lesley G. Shane. (2017) Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis. PharmacoEconomics 35:10, pages 1047-1062.
Crossref
Sonja Stavrik-Genadieva, Aleksandra Grozdanova, Katerina Netkovska-Ancevska, Magdalena Dimitrova-Genadieva & Gligor Dimitrov. (2017) Regulatory considerations of biosimilars and clinical dilema of their use. Sanamed 12:1, pages 45-50.
Crossref
A.M.M. Basso, G.S. Prado, P.B. Pelegrini & M.F. Grossi-de-Sa. 2017. Current Developments in Biotechnology and Bioengineering. Current Developments in Biotechnology and Bioengineering 23 48 .
Amit B. Agarwal & Ali McBride. (2016) Understanding the biosimilar approval and extrapolation process—A case study of an epoetin biosimilar. Critical Reviews in Oncology/Hematology 104, pages 98-107.
Crossref
Filipe C. Araújo, João Gonçalves & João Eurico Fonseca. (2016) Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?. Current Rheumatology Reports 18:8.
Crossref
Vincent T. Janmaat, Marco J. Bruno, Suzanne Polinder, Sylvie Lorenzen, Florian Lordick, Maikel P. Peppelenbosch & Manon C. W. Spaander. (2016) Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. PLOS ONE 11:4, pages e0153943.
Crossref
J. Harenberg, C. Cimminiello, G. Agnelli, G. Di Minno, H. Polo Friz, P. Prandoni & F. Scaglione. (2016) Biosimilars of low‐molecular‐weight heparin products: fostering competition or reducing ‘biodiversity’?. Journal of Thrombosis and Haemostasis 14:3, pages 421-426.
Crossref
Paul Declerck, Mourad Farouk-Rezk & Pauline M. Rudd. (2015) Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. Pharmaceutical Research 33:2, pages 261-268.
Crossref
Christina Mitropoulou, Vasilios Fragoulakis, Nada Bozina, Athanassios Vozikis, Svjetlana Supe, Tamara Bozina, Zdravka Poljakovic, Ron H van Schaik & George P Patrinos. (2015) Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Pharmacogenomics 16:2, pages 137-148.
Crossref
Paola M. Cutroneo, Valentina Isgrò, Alessandra Russo, Valentina Ientile, Laura Sottosanti, Giuseppe Pimpinella, Anita Conforti, Ugo Moretti, Achille P. Caputi & Gianluca Trifirò. (2014) Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database. Drug Safety 37:11, pages 961-970.
Crossref
Jay B. Wish. (2014) The Approval Process for Biosimilar Erythropoiesis-Stimulating Agents. Clinical Journal of the American Society of Nephrology 9:9, pages 1645-1651.
Crossref
Jame Abraham. (2014) Introduction and Commentary: Paving the Way for Biosimilars in Oncology, Part 3. Seminars in Oncology 41, pages S1-S2.
Crossref
David Henry & Carrie Taylor. (2014) Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars. Seminars in Oncology 41, pages S13-S20.
Crossref
J. Cortés, G. Curigliano & V. Diéras. (2014) Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Research and Treatment 144:2, pages 233-239.
Crossref
María-Isabel Farfan-Portet, Sophie Gerkens, Isabelle Lepage-Nefkens, Irmgard Vinck & Frank Hulstaert. (2013) Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?. The European Journal of Health Economics 15:3, pages 223-228.
Crossref
Saskia M Rombach, Carla EM Hollak, Gabor E Linthorst & Marcel GW Dijkgraaf. (2013) Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet Journal of Rare Diseases 8:1.
Crossref
Håkan Mellstedt. (2013) Clinical considerations for biosimilar antibodies. European Journal of Cancer Supplements 11:3, pages 1-11.
Crossref
Phill O’Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro & Jon Sussex. (2013) Projecting Expenditure on Medicines in the UK NHS. PharmacoEconomics 31:10, pages 933-957.
Crossref
Martina WeiseMarie-Christine BielskyKaren De SmetFalk EhmannNiklas EkmanThijs J. GiezenIordanis GravanisHans-Karl HeimEsa HeinonenKowid HoAlexandre MoreauGopalan NarayananNanna A. KruseGabriele ReichmannRobin ThorpeLeon van Aerts, Camille VleminckxMeenu WadhwaChristian K. Schneider. (2012) Biosimilars: what clinicians should know. Blood 120:26, pages 5111-5117.
Crossref
Richard P Rozek. (2012) Economics as a guide to developing public policies for biosimilar pharmaceutical products. Queen Mary Journal of Intellectual Property 2:4, pages 363-375.
Crossref
Zayrho Desanvicente-Celis, Arley Gomez-Lopez & Juan-Manuel Anaya. (2012) Similar biotherapeutic products: overview and reflections. Immunotherapy 4:12, pages 1841-1857.
Crossref
Abdol Majid Cheraghali. (2012) Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. DARU Journal of Pharmaceutical Sciences 20:1.
Crossref
Guillermina Forno & Eduardo Orti. (2017) Biosimilars: Current situation and future expectations. European Journal of Risk Regulation 3:2, pages 213-218.
Crossref
Chiara Loiacono, Carmela Sgroi, Salvatore Coppolino, Angelo Cannata, Rosarita Ferrara, Vincenzo Arcoraci, Pasquale Cananzi, Vincenzo Savica, Martijn Schuemie, Achille P. Caputi & Gianluca Trifirò. (2012) How Much are Biosimilars Used in Southern Italy?. BioDrugs 26:2, pages 113-120.
Crossref
Jorge Mestre-Ferrandiz & Adrian Towse. (2014) What is the Role of HTA for Biosimilars?. SSRN Electronic Journal.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.